Education

M.D. in Medicine, Medical School, University of California, Irvine, 1984

Current position

Staff Nephrologist, VA Northern California System of Clinics (1991-present)
Member, Physiology Graduate Group (1991-present)
Member, Cell and Developmental Biology Graduate Group, UCD (2000-present)
Member, UC Davis Cancer Center (2002-present)
Member, Biochemistry and Molecular Biology Graduate Group, UCD (2002-present)
Professor of Medicine, University of California, Davis, School of Medicine (2003-present)
Member, Immunology Graduate Group, UCD (2003-present)
Chief, Nephrology Section, Mather (Sacramento) VAMC (2004-present)
Member, Comparative Pathology Graduate Group (2006-present)
Editor-in-Chief, Cancers (2009-present)
Member, Genetics and Genomic Graduate Group (2014-present)

Publications (since 2010)

1. Taylor, S. L., Ruhaak, L. R., Kelly, K., Weiss, R. H. and Kim, K. (2016). Effects of imputation on correlation: implications for analysis of mass spectrometry data from multiple biological matrices. Brief Bioinform.
   
2. Kim, J., Ulu, A., Wan, D., Yang, J., Hammock, B. D. and Weiss, R. H. (2016). Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy. Mol Cancer Ther.
   
3. Elahi, S., Weiss, R. H. and Merani, S. (2016). Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS 30(2): 171-183.
   
4. Abu Aboud, O., Donohoe, D., Bultman, S., Fitch, M., Riiff, T., Hellerstein, M. and Weiss, R. H. (2015). PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth. Am J Physiol Cell Physiol 308(11): C890-898.
   
5. Mirzayans, R., Andrais, B., Scott, A., Wang, Y. W., Weiss, R. H. and Murray, D. (2015). Spontaneous gammaH2AX Foci in Human Solid Tumor-Derived Cell Lines in Relation to p21WAF1 and WIP1 Expression. Int J Mol Sci 16(5): 11609-11628.
   
6. Wettersten, H. I., Hakimi, A. A., Morin, D., Bianchi, C., Johnstone, M. E., Donohoe, D. R., Trott, J. F., Aboud, O. A., Stirdivant, S., Neri, B., Wolfert, R., Stewart, B., Perego, R., Hsieh, J. J. and Weiss, R. H. (2015). Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Cancer Res 75(12): 2541-2552.
   
7. Hwang, V. J., Kim, J., Rand, A., Yang, C., Sturdivant, S., Hammock, B., Bell, P. D., Guay-Woodford, L. M. and Weiss, R. H. (2015). The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. Am J Physiol Renal Physiol 309(6): F492-498. [Epub ahead of print]
   
8. Hoffman, M. D. and Weiss, R. H. (2015). Does Acute Kidney Injury From an Ultramarathon Increase the Risk for Greater Subsequent Injury? Clin J Sport Med.
   
9. Berthelot, C. C., Kamita, S. G., Sacchi, R., Yang, J., Nording, M. L., Georgi, K., Hegedus Karbowski, C., German, J. B., Weiss, R. H., Hogg, R. J., Hammock, B. D. and Zivkovic, A. M. (2015). Changes in PTGS1 and ALOX12 Gene Expression in Peripheral Blood Mononuclear Cells Are Associated with Changes in Arachidonic Acid, Oxylipins, and Oxylipin/Fatty Acid Ratios in Response to Omega-3 Fatty Acid Supplementation. PLoS One 10(12): e0144996.
   
10. Wecksler, A. T., Hwang, S. H., Liu, J. Y., Wettersten, H. I., Morisseau, C., Wu, J., Weiss, R. H. and Hammock, B. D. (2015). Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemother Pharmacol 75(1): 161-171.
    
11. Hoffman, M. D., Stuempfle, K. J., Sullivan, K. and Weiss, R. H. (2015). Exercise-associated hyponatremia with exertional rhabdomyolysis: importance of proper treatment. Clin Nephrol 83(4): 235-242.
    
12. Tan, M., Wettersten, H. I., Chu, K., Huso, D. L., Watnick, T., Friedlander, S., Landesman, Y. and Weiss, R. H. (2014). Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels. Am J Physiol Renal Physiol 307(11): F1179-1186.
    
13. Wettersten, H. I., Landesman, Y., Friedlander, S., Shacham, S., Kauffman, M. and Weiss, R. H. (2014). Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. PLoS One 9(12): e113867.
    
14. Hwang, V. J., Ulu, A., van Hoorebeke, J. and Weiss, R. H. (2014). Biomarkers in IgA nephropathy. Biomark Med 8(10): 1263-1277.
    
15. Wecksler, A. T., Hwang, S. H., Wettersten, H. I., Gilda, J. E., Patton, A., Leon, L. J., Carraway, K. L., 3rd, Gomes, A. V., Baar, K., Weiss, R. H. and Hammock, B. D. (2014). Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB. Anticancer Drugs 25(4): 433-446.
    
16. Wettersten, H. I., Ganti, S. and Weiss, R. H. (2014). Metabolomic profiling of tumor-bearing mice. Methods Enzymol 543: 275-296.
    
17. Wettersten, H.I., Weiss, R.H. Kidney disease, in Nicholls, A., Theodoridis, G., Wilson, I.D. eds: Global Metabolomic Profiling: Clinical Applications, 2014Future Medicine,
    
18. Hoffman, M. D. and Weiss, R. H. (2014). Symptomatic hypotonic hyponatremia presenting at high altitude. Wilderness Environ Med 25(3): 362-363.
    
19. Zhang, G., Panigrahy, D., Hwang, S. H., Yang, J., Mahakian, L. M., Wettersten, H. I., Liu, J. Y., Wang, Y., Ingham, E. S., Tam, S., Kieran, M. W., Weiss, R. H., Ferrara, K. W. and Hammock, B. D. (2014). Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. Proc Natl Acad Sci U S A 111(30): 11127-11132.
    
20. Gupta, R., Dong, Y., Solomon, P. D., Wettersten, H. I., Cheng, C. J., Min, J. N., Henson, J., Dogra, S. K., Hwang, S. H., Hammock, B. D., Zhu, L. J., Reddel, R. R., Saltzman, W. M., Weiss, R. H., Chang, S., Green, M. R. and Wajapeyee, N. (2014). Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proc Natl Acad Sci U S A 111(30): E3062-3071.
    
21. Han, J., Tan, M., Sudheendra, L., Weiss, R. H. and Kennedy, I. M. (2014). On-chip detection of a single nucleotide polymorphism without polymerase amplification. Nano Res 7(9): 1302-1310.
    
22. Aboud, O. A. and Weiss, R. H. (2013). New opportunities from the cancer metabolome. Clin Chem 59(1): 138-146.
    
23. Wettersten, H. I., Hee Hwang, S., Li, C., Shiu, E. Y., Wecksler, A. T., Hammock, B. D. and Weiss, R. H. (2013). A novel p21 attenuator which is structurally related to sorafenib. Cancer Biol Ther 14(3): 278-285.
    
24. Martin, K. S., Soldi, C., Candee, K. N., Wettersten, H. I., Weiss, R. H. and Shaw, J. T. (2013). From bead to flask: Synthesis of a complex β-amido-amide for probe-development studies. Beilstein J Org Chem 9: 260-264.
    
25. Ulu, A., Harris, T. R., Morisseau, C., Miyabe, C., Inoue, H., Schuster, G., Dong, H., Iosif, A. M., Liu, J. Y., Weiss, R. H., Chiamvimonvat, N., Imig, J. D. and Hammock, B. D. (2013). Anti-inflammatory effects of omega-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol 62(3): 285-297.
    
26. Liu, R., Wettersten, H. I., Park, S. H. and Weiss, R. H. (2013). Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer. Future Med Chem 5(9): 991-994.
    
27. Wettersten, H. I. and Weiss, R. H. (2013). Potential biofluid markers and treatment targets for renal cell carcinoma. Nat Rev Urol 10(6): 336-344.
    
28. Zhang, G., Panigrahy, D., Mahakian, L. M., Yang, J., Liu, J. Y., Stephen Lee, K. S., Wettersten, H. I., Ulu, A., Hu, X., Tam, S., Hwang, S. H., Ingham, E. S., Kieran, M. W., Weiss, R. H., Ferrara, K. W. and Hammock, B. D. (2013). Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A 110(16): 6530-6535.
    
29. Zivkovic, A. M., Yang, J., Georgi, K., Hegedus, C., Nording, M. L., O'Sullivan, A., German, J. B., Hogg, R. J., Weiss, R. H., Bay, C. and Hammock, B. D. (2012). Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations. Metabolomics 8(6): 1102-1113.
    
30. Mall, C., Rocke, D. M., Durbin-Johnson, B. and Weiss, R. H. (2013). Stability of miRNA in human urine supports its biomarker potential. Biomark Med 7(4): 623-631.
    
31. Wettersten, H. I. and Weiss, R. H. (2013). Applications of metabolomics for kidney disease research: from biomarkers to therapeutic targets. Organogenesis 9(1): 11-18.
    
32. Abu Aboud, O., Wettersten, H. I. and Weiss, R. H. (2013). Inhibition of PPARalpha induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells. PLoS One 8(8): e71115.
    
33. Nording, M. L., Yang, J., Georgi, K., Hegedus Karbowski, C., German, J. B., Weiss, R. H., Hogg, R. J., Trygg, J., Hammock, B. D. and Zivkovic, A. M. (2013). Individual variation in lipidomic profiles of healthy subjects in response to omega-3 Fatty acids. PLoS One 8(10): e76575.
    
34. Kim, K., Mall, C., Taylor, S. L., Hitchcock, S., Zhang, C., Wettersten, H. I., Jones, A. D., Chapman, A. and Weiss, R. H. (2014). Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment. PLoS One 9(1): e86223.
    
35. Ganti, S., Taylor, S. L., Kim, K., Hoppel, C. L., Guo, L., Yang, J., Evans, C. and Weiss, R. H. (2012). Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer 130(12): 2791-2800.
    
36. Ganti, S., Taylor, S. L., Abu Aboud, O., Yang, J., Evans, C., Osier, M. V., Alexander, D. C., Kim, K. and Weiss, R. H. (2012). Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res 72(14): 3471-3479.
    
37. Zivkovic, A. M., Yang, J., Georgi, K., Hegedus, C., Nording, M. L., O'Sullivan, A., German, J. B., Hogg, R. J., Weiss, R. H., Bay, C. and Hammock, B. D. (2012). Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations. Metabolomics 8(6): 1102-1113.
    
38. Hoffman, M. D., Stuempfle, K. J., Fogard, K., Hew-Butler, T., Winger, J. and Weiss, R. H. (2013). Urine dipstick analysis for identification of runners susceptible to acute kidney injury following an ultramarathon. J Sports Sci 31(1): 20-31. [Epub ahead of print]
    
39. Inoue, H., Kauffman, M., Shacham, S., Landesman, Y., Weiss, R.H. Inhibition of nuclear export by CRM1 attenuation causes apoptosis in kidney cancer cells. Journal of Urology, 2012 Oct 15. S0022-5347(12)05217-2. [Epub ahead of print]
    
40. Chen, H., Li, C., Huang, J., Cung, T., Seiss, K., Beamon, J., Carrington, M. F., Porter, L. C., Burke, P. S., Yang, Y., Ryan, B. J., Liu, R., Weiss, R. H., Pereyra, F., Cress, W. D., Brass, A. L., Rosenberg, E. S., Walker, B. D., Yu, X. G. and Lichterfeld, M. (2011). CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 121(4): 1549-1560.
    
41. Weiss, R. H., Inoue H. (2011). Diagnosis and Treatment of Kidney Cancer. Nephrology CyberRounds.
    
42. Kim, K., Taylor, S. L., Ganti, S., Guo, L., Osier, M. V. and Weiss, R. H. (2011). Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS 15(5): 293-303.
    
43. Ganti, S. and Weiss, R. H. (2011). Urine metabolomics for kidney cancer detection and biomarker discovery. Urol Oncol 29(5): 551-557.
    
44. Buzon, M. J., Seiss, K., Weiss, R., Brass, A. L., Rosenberg, E. S., Pereyra, F., Yu, X. G. and Lichterfeld, M. (2011). Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. J Virol 85(18): 9646-9650.
    
45. Inoue, H., Hwang, S. H., Wecksler, A. T., Hammock, B. D. and Weiss, R. H. (2011). Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther 12(9): 827-836.
    
46. Weiss, R. H. and Kim, K. (2012). Metabolomics in the study of kidney diseases. Nat Rev Nephrol 8(1): 22-33.
    
47. Taylor, S. L., Ganti, S., Bukanov, N. O., Chapman, A., Fiehn, O., Osier, M., Kim, K. and Weiss, R. H. (2010). A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am J Physiol Renal Physiol 298(4): F909-922.
    
48. Ishimaru, T., Lau, J., Jackson, A. L., Modiano, J. F. and Weiss, R. H. (2010). Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma. J Urol 184(5): 2143-2149.